Floatz logo

ANTI-CD22/PBD ADC ADCT-602

Philadelphia Chromosome Positive

M.D. Anderson Cancer Centerantibody_drug_conjugatePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Philadelphia Chromosome Positive cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BB
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 3BB
Blinatumomab
M.D. Anderson Cancer Center
Phase 2BB
VINCRISTINE SULFATE
M.D. Anderson Cancer Center
Phase 3BB
DEXAMETHASONE
M.D. Anderson Cancer Center
Phase 3BB

View all 28 →

Same molecule, other indications

ANTI-CD22/PBD ADC ADCT-602 is also rated in:

myelodysplastic syndrome with excess blastsDormant
CCC
Indicative ·
48 / 100
View asset →
CD22 PositiveDormant
CCC
Indicative ·
48 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →